Anixa Biosciences, Inc.
ANIX · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $9 | $0 | $0 |
| Gross Profit | $0 | -$9 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,055 | $1,322 | $1,552 | $1,476 |
| G&A Expenses | $1,381 | $1,681 | $1,834 | $1,687 |
| SG&A Expenses | $1,381 | $1,681 | $1,834 | $1,687 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,436 | $3,003 | $3,386 | $3,163 |
| Operating Income | -$2,436 | -$3,003 | -$3,386 | -$3,163 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $190 | $173 | $250 |
| Pre-Tax Income | $0 | -$2,813 | -$3,213 | -$2,913 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$2,790 | -$3,184 | -$2,883 |
| % Margin | – | – | – | – |
| EPS | -0.07 | -0.087 | -0.099 | 0.3 |
| % Growth | 19.2% | 12.4% | -133% | – |
| EPS Diluted | -0.07 | -0.087 | -0.1 | 0.3 |
| Weighted Avg Shares Out | 32,476 | 32,202 | 32,197 | 31,898 |
| Weighted Avg Shares Out Dil | 32,476 | 32,202 | 32,197 | 31,898 |
| Supplemental Information | – | – | – | – |
| Interest Income | $156 | $190 | $173 | $250 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $9 | $0 | $9 |
| EBITDA | -$2,436 | -$2,994 | -$3,386 | -$3,154 |
| % Margin | – | – | – | – |